Does the CFIA continue to apply the precautionary approach after evaluators have approved new biotechnology-derived agricultural products?
Follow-up, which includes further research and monitoring, is also part of the precautionary approach. Monitoring approved products helps to reduce uncertainty and contributes to improved decision making as scientific knowledge evolves. The precautionary approach also requires that mechanisms be in place to allow the CFIA to re-evaluate decisions and conduct further consultation, if these become necessary. For these reasons, anyone who has had a biotechnology-derived seed product approved in Canada, for example, has a legal obligation, under the Seeds Regulations, to report back to the CFIA any new information regarding risks to the environment, including risk to human health, resulting from the release of the seed. The CFIA reviews that information and takes action as appropriate.
